Track topics on Twitter Track topics that are important to you
BERLIN, Sept. 1, 2016 /PRNewswire/ -- At this year's Internationale Funkausstellung (IFA), taking place in Berlin, Germany from September 2-7, Royal Philips (NYSE: PHG, AEX: PHIA) is presenting innova...
MEMPHIS, Tenn., Aug. 12, 2016 /PRNewswire/ -- Royal Philips (NYSE:PHG, AEX: PHIA) today (August 12, 2016) unveiled 'A little more action' at Elvis Week in Memphis, Tennessee. 'A little more action' te...
Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different (68)Ge/(68)Ga-Generators: Pharmacokinetics and Biodistribution in Nonhuman Primates and Demonstration of Solitary Pulmonary Nodule Imaging in Humans.
Radiopharmaceuticals containing the motive tripeptide arginyl-glycyl-asparatic acid (RGD) are known to target ανβ3 integrins during tumor angiogenesis. A more generic kit radiolabeling procedure ac...
Molecular imaging of programmed cell death (apoptosis) in vivo is an innovative strategy for early assessment of treatment response and treatment efficacy in cancer patients. Externalization of phosph...
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
We performed pretreatment angiogenesis imaging (Ga-NOTA-arginyl-glycyl-aspartic acid [RGD] PET/CT) to compare its prognostic value to dynamic contrast-enhanced (DCE) MRI in breast cancer patients.
Misconceptions about if and how living donors may receive financial support appear to be widespread. These misconceptions may be perpetuated by unclear or incomplete language in informed consent docum...
Radiolabeled arginine-glycine-aspartic acid (RGD) peptides have been developed for PET imaging of integrin avβ3 in the tumor vasculature, leading to great potential for noninvasively evaluating tumor...